Literature DB >> 21541825

Inguinopelvic lymphadenectomy following positive inguinal sentinel lymph node biopsy in melanoma: true frequency of synchronous pelvic metastases.

Carrie K Chu1, Keith A Delman, Grant W Carlson, Andrea C Hestley, Douglas R Murray.   

Abstract

BACKGROUND: True frequency of synchronous pelvic metastases with positive inguinal sentinel lymph node (SLN) biopsy is unknown. Role of pelvic dissection in the SLN era is unclear.
METHODS: From 1994 to 2004, 1 surgeon routinely performed nonselective, complete inguinopelvic lymphadenectomy after positive inguinal SLN biopsy. All cases were identified from a prospectively maintained database. Clinicopathologic features associated with pelvic disease were assessed.
RESULTS: A total of 40 patients with positive inguinal SLN underwent, without additional selection, 42 complete inguinopelvic lymphadenectomies. Median age was 46.5 years (range 25-79 years); 79% had lower extremity primaries. Median Breslow depth was 2.3 mm (range 1.0-10.0 mm), Clark's IV/V 98%, ulceration 26%. Frequency of synchronous pelvic disease upon completion lymphadenectomy was 5 of 42 (11.9%). Patients with and without pelvic disease were similar in age, sex, Breslow depth, Clark's level, ulceration, and mitoses. All 5 cases with pelvic metastases had extremity primaries (4 distal, 1 proximal). Of the 5, 3 (60%) had ≥3 total involved inguinal nodes, compared with only 1 (2.7%) of the 37 cases without pelvic disease (P=.003). Ratio of positive to total number inguinal nodes retrieved was >0.20 in 80% of cases with pelvic disease and 8.6% of cases without (P=.002). Upon lymphoscintigraphy review, secondary pelvic drainage was present in 80% of cases with pelvic disease compared with 56% of cases without pelvic disease, though the trend was statistically insignificant (P=.63).
CONCLUSIONS: In this cohort of unselected, SLN-positive patients with complete inguinopelvic lymphadenectomy, frequency of synchronous pelvic disease was 11.9%. Patients with ≥3 total involved inguinal nodes or inguinal node ratio >0.20 appear more likely to harbor pelvic disease.

Entities:  

Mesh:

Year:  2011        PMID: 21541825      PMCID: PMC5891327          DOI: 10.1245/s10434-011-1750-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  19 in total

1.  Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma.

Authors:  Andrew J Page; Grant W Carlson; Keith A Delman; Douglas Murray; Andrea Hestley; Cynthia Cohen
Journal:  Am Surg       Date:  2007-07       Impact factor: 0.688

2.  Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.

Authors:  Brian Badgwell; Yan Xing; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Merrick I Ross; Janice N Cormier
Journal:  Ann Surg Oncol       Date:  2007-08-01       Impact factor: 5.344

3.  Frequency of nonsentinel lymph node metastasis in melanoma.

Authors:  Kelly M McMasters; Sandra L Wong; Michael J Edwards; Celia Chao; Merrick I Ross; R Dirk Noyes; Vicki Viar; Patricia B Cerrito; Douglas S Reintgen
Journal:  Ann Surg Oncol       Date:  2002-03       Impact factor: 5.344

4.  Extent of lymph node dissection in melanoma of the trunk or lower extremity.

Authors:  D G Coit; M F Brennan
Journal:  Arch Surg       Date:  1989-02

5.  Groin dissection in malignant melanoma.

Authors:  C P Karakousis; D L Driscoll; B Rose; D L Walsh
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

6.  Does the extent of operation influence the prognosis in patients with melanoma metastatic to inguinal nodes?

Authors:  G B Mann; D G Coit
Journal:  Ann Surg Oncol       Date:  1999 Apr-May       Impact factor: 5.344

7.  Surgical management of malignant melanoma using dynamic lymphoscintigraphy and gamma probe-guided sentinel lymph node biopsy: the Emory experience.

Authors:  D R Murray; G W Carlson; R Greenlee; N Alazraki; C Fry-Spray; A Hestley; R Poole; M Blais; D S Timbert; J Vansant
Journal:  Am Surg       Date:  2000-08       Impact factor: 0.688

8.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

9.  Radical dissection after positive groin sentinel biopsy in melanoma patients: rate of further positive nodes.

Authors:  Mario Santinami; Antonino Carbone; Federica Crippa; Andrea Maurichi; Cristina Pellitteri; Roberta Ruggeri; Odysseas Zoras; Roberto Patuzzo
Journal:  Melanoma Res       Date:  2009-04       Impact factor: 3.599

10.  Lymph node ratio predicts disease-specific survival in melanoma patients.

Authors:  Yan Xing; Brian D Badgwell; Merrick I Ross; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Anthony Lucci; Janice N Cormier
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

View more
  2 in total

1.  Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin.

Authors:  D Verver; M F Madu; C M C Oude Ophuis; M Faut; J H W de Wilt; J J Bonenkamp; D J Grünhagen; A C J van Akkooi; C Verhoef; B L van Leeuwen
Journal:  Br J Surg       Date:  2017-11-02       Impact factor: 6.939

2.  Pelvic sentinel lymph nodes have minimal impact on survival in melanoma patients.

Authors:  Mikko Vuoristo; Timo Muhonen; Virve Koljonen; Susanna Juteau; Micaela Hernberg; Suvi Ilmonen; Tiina Jahkola
Journal:  BJS Open       Date:  2021-11-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.